Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Edmond Bendaly"'
Autor:
Khalil Diab, Christy Costanian, Marvi Bikak, Nawar Al Nasrallah, Ahmad A. Al-Hader, Edmond Bendaly, Chen Zhang, Rita Assi
Publikováno v:
Southern Medical Journal. 116:202-207
Autor:
Kenneth W. Culver, Philip Galebach, Edmond Bendaly, Alexander R. Macalalad, Anand A. Dalal, Medha Sasane, Rebekah Foster, Iryna Bocharova, Annie Guerin
Publikováno v:
Advances in Therapy. 34:1145-1156
This study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and early outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC) who received ceritinib in US clinical practice. US o
Autor:
Shashank Nuguru, Chen Zhang, Samih Raad, Houssam Oueini, Khalil Diab, Edmond Bendaly, Nasser H. Hanna, Shadia I. Jalal
Publikováno v:
Southern medical journal. 111(8)
OBJECTIVES Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the primary method for the diagnosis and staging of lung cancer. The purpose of this study was to assess the yield of EBUS-TBNA in the subtyping and genotyping
Autor:
Alexander R. Macalalad, Philip Galebach, Anand A. Dalal, Rebekah Foster, Medha Sasane, Edmond Bendaly, Kenneth W. Culver, Iryna Bocharova, Annie Guerin
Publikováno v:
Advances in therapy. 34(7)
Crizotinib is recommended as first-line therapy for ALK-positive non-small cell lung cancer (NSCLC), but within a year of treatment initiation many patients develop resistance. With the recent approval of second-generation ALK inhibitors, this study
Autor:
Philip Galebach, Adam Nosal, Oscar Arrieta, Keunchil Park, Miklos Pless, Edmond Bendaly, Elyse Swallow, Medha Sasane, Jie Zhang, Karen Stein, Jacques Cadranel, R Degun, Andrew Kageleiry, Dony Patel
Publikováno v:
Lung Cancer
Lung Cancer, Elsevier, 2016, 98, pp.9-14. ⟨10.1016/j.lungcan.2016.05.004⟩
Lung Cancer, 2016, 98, pp.9-14. ⟨10.1016/j.lungcan.2016.05.004⟩
Lung Cancer, Elsevier, 2016, 98, pp.9-14. ⟨10.1016/j.lungcan.2016.05.004⟩
Lung Cancer, 2016, 98, pp.9-14. ⟨10.1016/j.lungcan.2016.05.004⟩
Objectives Second-generation ALK inhibitors are recently available for ALK + non-small cell lung cancer (NSCLC) patients previously treated with crizotinib. This study described characteristics, treatment sequencing, and outcomes among locally advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a013a13ecfe36113ffea5f3e398bac
https://hal.sorbonne-universite.fr/hal-01314916/file/Cadranel_Characteristics,.pdf
https://hal.sorbonne-universite.fr/hal-01314916/file/Cadranel_Characteristics,.pdf
Autor:
Rebekah Foster, Philip Galebach, Anand A. Dalal, Gero Struebbe, Edmond Bendaly, Kenneth W. Culver, Iryna Bocharova, Annie Guerin
Publikováno v:
Journal of Thoracic Oncology. 12:S1175-S1176
Publikováno v:
Journal of Thoracic Oncology. 12:S658-S659
Autor:
Rebekah Foster, Iryna Bocharova, Philip Galebach, Gero Struebbe, Anand A. Dalal, Annie Guerin, Kenneth W. Culver, Edmond Bendaly
Publikováno v:
Journal of Thoracic Oncology. 11:S314-S315
Autor:
Anand A. Dalal, Philip Galebach, Gero Struebbe, Kenneth W. Culver, Rebekah Foster, Iryna Bocharova, Edmond Bendaly, Annie Guerin
Publikováno v:
Journal of Thoracic Oncology. 12:S1163
Publikováno v:
Chest. 150:707A